Richmond Pediatric Associates

CLIA Laboratory Citation Details

3
Total Citations
12
Total Deficiencyies
9
Unique D-Tags
CMS Certification Number 49D0227389
Address 9900 Independence Park Drive - Suite 100, Richmond, VA, 23233
City Richmond
State VA
Zip Code23233
Phone804 747-1750
Lab DirectorWILL GUTHRIE

Citation History (3 surveys)

Survey - April 23, 2026

Survey Type: Special

Survey Event ID: QT1I11

Deficiency Tags: D0000 D2130 D6000 D6016 D2016 D2121

Summary:

Summary Statement of Deficiencies D0000 An off-site CLIA proficiency testing (PT) desk review was conducted for Richmond Pediatric Associates, INC on April 23, 2026 by the Virginia Department of Health's Office of Licensure and Certification. The laboratory was surveyed under 42 CFR part 493 CLIA Requirements. The laboratory was found to be out of compliance with the following CONDITION LEVEL DEFICIENCIES: D2016 - 42 CFR. 493.803 Condition: Successful Participation D6000 - 42 CFR. 493.1403 Condition: Laboratories performing moderate complexity testing- Laboratory Director D2016 SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS- approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- Based on a desk review of the Certification and Survey Provider Enhanced Reporting, the laboratory's College of American Pathologists proficiency testing (PT) records, and interview, the laboratory failed to attain a score of at least eighty percent of acceptable responses for regulated analyte, Red Blood Cell Count, on two of three hematology testing events reviewed, resulting in an initial unsuccessful PT performance. Refer to D2130 D2121 HEMATOLOGY CFR(s): 493.851(a) (a) Failure to attain a score of at least 80 percent of acceptable responses for each analyte in each testing event is unsatisfactory analyte performance for the testing event. This STANDARD is not met as evidenced by: Based on a desk review of the CASPER 0155 report, the laboratory's proficiency testing (PT) evaluation records, and interview, the laboratory failed to achieve a score of at least eighty percent (80%), for Hematocrit (HCT) on the 2026 College of American Pathologists (CAP) PT Event 1, resulting in unsatisfactory performance. Findings include: 1. Review of the CASPER 0155 report revealed the laboratory's Hematology 2026 Event 1 recorded an unsatisfactory HCT score of 20%. 2. Desk review of the laboratory's CAP Hematology PT records on 4/23/26 revealed: 2026 Event 1- HCT scored 20%, the laboratory received unacceptable scores on the following four of five challenges: FH-01 reported as 47.80 with acceptable range 43.38-47.01; FH-02 reported as 37.90 with acceptable range 34.88-37.80; FH-03 reported as 21.20 with acceptable range 19.39-21.02; FH-04 reported as 58.70 with acceptable range 53.34-57.80); resulting in unsatisfactory performance, with CAP noting "at risk for next two PT mailings". 3. A virtual interview with the Medical Assistant/ Lab Manager on 4/23/26 at 3 PM confirmed the above findings. D2130 HEMATOLOGY CFR(s): 493.851(f) (f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on a desk review of the laboratory's CASPER 0155 report, the laboratory's proficiency testing (PT) evaluation records, and interview, the laboratory failed to achieve satisfactory performance, a score of at least eighty percent (80%), for Red Blood Cell (RBC) on two of three hematology testing events resulting in initial unsuccessful participation. Findings include: 1. Review of the CASPER 0155 report revealed the following unsatisfactory scores: Hematology 2025- Event 2 - 60% for analyte 0775 RBC; Hematology 2026- Event 1 - 60% for analyte 0775 RBC. 2. Desk review of the laboratory's College of American Pathologists (CAP) PT records on 4/23 /26 revealed: CAP 2025 Hematology Event 2: RBC scored 60% (challenge sample FH 08 reported as 3.69 with acceptable range 3.71-4.03, challenge sample FH-09 reported as 5.74 with acceptable range 5.80-6.29); CAP 2026 Hematology Event 1: RBC scored 60% (challenge sample FH-01 reported as 5.01 with acceptable range 4.59- 4.99, challenge sample FH-04 reported as 5.84 with acceptable range 5.36-5.82); resulting in an initial unsuccessful participation for analyte RBC. 3. A virtual -- 2 of 3 -- interview with the Medical Assistant/ Lab Manager on 4/23/26 at 3 PM confirmed the above findings. D6000 MODERATE COMPLEXITY LABORATORY DIRECTOR CFR(s): 493.1403 The laboratory must have a director who meets the qualification requirements of 493. 1405 of this subpart and provides overall management and direction in accordance with 493.1407 of this subpart. This CONDITION is not met as evidenced by: Based on a review of the Certification and Survey Provider Enhanced Reporting CASPER 0155 report, proficiency testing records, and interview, the laboratory director failed to provide overall direction and management of the laboratory services in ensuring satisfactory and successful participation in an approved Health and Human Services approved proficiency program. Refer to D6016 D6016 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1407(e)(4)(i) (e)(4)(i) The proficiency testing samples are tested as required under Subpart H of this part; This STANDARD is not met as evidenced by: Based on a desk review of the CASPER 0155 report, proficiency testing records, and interview, the laboratory director failed to ensure: 1. satisfactory performance in the Health and Human Services (HHS) approved program for Hematocrit on the first testing event of 2026 - Refer to D2121; 2. successful participation in the laboratory's HHS approved program for Red Blood Cell count on two of three consecutive testing events in 2025 and year to date 2026 - Refer to D2130. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - January 10, 2025

Survey Type: Standard

Survey Event ID: 16TH11

Deficiency Tags: D5421 D5421 D0000

Summary:

Summary Statement of Deficiencies D0000 An announced CLIA recertification survey was conducted at Richmond Pediatric Associates on January 10, 2025 by the Virginia Department of Health's Office of Licensure and Certification. The laboratory was surveyed under 42 CFR part 493 CLIA regulations. Specific deficiency cited as follows. D5421 ESTABLISHMENT AND VERIFICATION OF PERFORMANCE CFR(s): 493.1253(b)(1) (b) Each laboratory that introduces an unmodified, FDA-cleared or approved test system must do the following before reporting patient test results: (b)(1)(i) Demonstrate that it can obtain performance specifications comparable to those established by the manufacturer for the following performance characteristics: (b)(1)(i) (A) Accuracy. (b)(1)(i)(B) Precision. (b)(1)(i)(C) Reportable range of test results for the test system. (b)(1)(ii) Verify that the manufacturer's reference intervals (normal values) are appropriate for the laboratory's patient population. This STANDARD is not met as evidenced by: Based on a review of laboratory's Hematology quality control reports, instrument performance verification records, and interviews, the laboratory director (LD) failed to document an evaluation/verification of the start-up studies of the Medonic Hematology analyzer prior to patient use in March 2023. Findings include: 1. Review of the laboratory's 2023 and 2024 STRECK STATS Quality control reports (lab account # 08803) revealed two Hematology instrument serial numbers: 031215- 006448 in January 2023, then 030722-010486. 2. An interview with the lab manager at approximately 11:00 am confirmed the laboratory received a new Medonic Hematology Analyzer in March of 2023. 3. Review of the laboratory's instrument validation records revealed instrument set-up, and instillation of the new Medonic Hematology instrument (Serial #030722-010486) on 3/21/23. The start-up documentation included precision, carryover, calibration, confirmation of Quality Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- Control values, linearity, along with 20 comparison samples, and 20 normal range samples. The validation documentation lacked evidence of laboratory director evaluation or review of the verification studies. 4. In an exit interview on 1/10/25 at approximately 12:4 with the nurse manager and lab manager, the above findings were confirmed. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - January 30, 2023

Survey Type: Standard

Survey Event ID: 09ZN11

Deficiency Tags: D0000 D2123 D5445

Summary:

Summary Statement of Deficiencies D0000 An announced CLIA Recertification survey was conducted at the Richmond Pediatric Associates on 01/30/23 by the Virginia Department of Health's Office of Licensure and Certification. The laboratory was surveyed under 42 CFR part 493 CLIA Requirements. Specific deficiencies cited are as follows: The laboratory is performing COVID-19 testing and is in compliance with the applicable COVID-19 reporting requirements. D2123 HEMATOLOGY CFR(s): 493.851(c) Failure to participate in a testing event is unsatisfactory performance and results in a score of 0 for the testing event. Consideration may be given to those laboratories failing to participate in a testing event only if-- (1) Patient testing was suspended during the time frame allotted for testing and reporting proficiency testing results; (2) The laboratory notifies the inspecting agency and the proficiency testing program within the time frame for submitting proficiency testing results of the suspension of patient testing and the circumstances associated with failure to perform tests on proficiency testing samples; and (3) The laboratory participated in the previous two proficiency testing events. This STANDARD is not met as evidenced by: Based on the review of the CASPER 0096D CLIA Application and Survey Summary Report, proficiency testing (PT) records and an interview, the laboratory failed to participate in one of four Complete Blood Count (CBC) events reviewed. Record review included third PT event in 2021 and three PT events in 2022. Findings include: 1. Review of the CASPER 0096D CLIA Application and Survey Summary Report and the College of American Pathologists (CAP) PT records for the third event in 2021 and three events in 2022 revealed the laboratory received a score of 0% for the following event: 2022 Event 1 FH A - 0%- for the CBC module (Notation by CAP- Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- failure to receive results). 2. An exit interview with the testing personnel on 01/30/23 at 1510 confirmed the findings. D5445 CONTROL PROCEDURES CFR(s): 493.1256(d)(1)(2)(g) Unless CMS Approves a procedure, specified in Appendix C of the State Operations Manual (CMS Pub. 7), that provides equivalent quality testing, the laboratory must-- (d)(1) Perform control procedures as defined in this section unless otherwise specified in the additional specialty and subspecialty requirements at 493.1261 through 493.1278. (d)(2) For each test system, perform control procedures using the number and frequency specified by the manufacturer or established by the laboratory when they meet or exceed the requirements in paragraph (d)(3) of this section. (g) The laboratory must document all control procedures performed. This STANDARD is not met as evidenced by: Based on a tour of the laboratory, review of policy and procedures (P&P), quality control (QC) records, lack of documentation, patient test data and interview, the lab failed to follow the established P&P of performing external QC materials with every new shipment and new lot number of assay kits for two of 15 lot numbers received from 06/01/21 up to the date of survey on 01/30/23, reporting 110 patients. Findings include: 1. A tour of the lab on 01/30/23 at approximately 1215 revealed the lab utilized the Quidel Solana instrument to perform the Solana GAS assay for the detection of Group A beta-hemolytic Streptococcus. 2. Review of the P&P revealed an Individualized Quality Control Plan (IQCP), approved by the lab director on 11/16 /18, that defined performing external QC materials every new shipment and new lot number of assay kits for the abovementioned analyte. 3. Review of QC records and patient test data from 06/01/21 up to the date of survey on 01/30/23 revealed lack of documentation of external QC materials for the following of assay kits: Lot number 183020 (expiration date 08/07/22) utilized from 07/22/21 to 09/24/21 and reporting 65 patients; Lot number 191098 (expiration date 01/08/23) utilized from 09/25/21 to 10 /27/21 and reporting 45 patient. 4. An exit interview with the testing personnel on 01 /30/23 at approximately 1520 confirmed the findings. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access